Neurological disorders affect millions of people worldwide, impacting the brain and nervous system and significantly affecting quality of life. Managing these conditions can be challenging for patients and their families. Through NeuroCytonix, Dr. Trujillo is dedicated to advancing research into potential approaches for neurological disorders that have been considered incurable.

Dr. Trujillo founded NeuroCytonix in 2017 as a biomedical technology company exploring and researching innovative solutions for neurological disorders. The company is headquartered in Rockville, Maryland, within the Maryland Biotech Corridor. In 2018, he established NeuroCytonix Mexico, which operates a state-of-the-art clinical research center in Monterrey, Mexico.

The core technology currently under research is designed for functional neurogenesis stimulation (FNS). The investigational medical device was developed by Dr. Rajah V. Kumar, a researcher in biophysics, radiobiology, and regenerative tissue engineering. NeuroCytonix’s approach to neurological disorders is based on the NeuroCytonics program, established in 2014 by Dr. Trujillo and Dr. Kumar. This program integrates principles from molecular neuroscience, engineering, and quantum physics. The model relies on exploring the regenerative potential of neuronal progenitor or dormant cells in neuroregeneration. Dr. Trujillo collaborated with Dr. Kumar to develop investigational FNS protocols for neurological disorders.

The investigational technology utilizes non-invasive, low-spectrum radio frequencies to generate instantaneous electromagnetic fields, which is being studied for its potential effects on cellular activity in the brain. This investigational technology is being evaluated for its potential applications in neurological conditions such as cerebral palsy, autism, stroke, traumatic brain injury (TBI), vascular dementia, and the neurological impacts of COVID-19.

In 2019, Dr. Trujillo and his team conducted a Randomized Controlled Trial (RCT) at the NeuroCytonix Mexico Clinical Research Center to evaluate the investigational protocol for cerebral palsy. The study assessed the protocol in terms of safety and efficacy in accordance with regulatory guidelines. The Mexican regulatory authority, COFEPRIS, acknowledged the results of NeuroCytonix’s cerebral palsy clinical trial and approved the protocol within Mexico. Manuscripts detailing the study’s findings are being prepared for submission to scientific journals.

Dr. Trujillo and his team are continuing their research efforts and working toward further regulatory evaluations, including a potential FDA review of the investigational cerebral palsy protocol. They remain committed to advancing research and exploring investigational protocols developed for other neurological disorders.

*The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. 

*COFEPRIS is a member of the International Council of Harmonization (ICH) and Pharmaceutical Inspection Cooperation Scheme (PIC/S) and is a Level IV National Regulatory Authority competent and efficient in the performance of the health regulatory functions recommended by PAHO / WHO.